Form 4: NeuroOne Medical Technologies CEO David Rosa Disposes of Shares to Cover Tax Obligations
SEC Form 4 Filing
David Rosa, CEO and President of NeuroOne Medical Technologies, disposed of 71,325 shares of common stock on February 18, 2025, to satisfy tax obligations.
Summary
- On February 18, 2025, David A. Rosa, CEO and President of NeuroOne Medical Technologies, disposed of 71,325 shares of common stock.
- The transaction was executed at a price of $1.16 per share.
- Following the transaction, Rosa directly owns 1,063,747 shares of NeuroOne Medical Technologies.
- The disposition was related to covering tax obligations.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a stock disposal for tax purposes. It doesn't inherently indicate positive or negative sentiment, but rather a routine financial transaction.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. Disposals to cover tax obligations are common.
Stakeholder Impact
- The disposal of shares by the CEO could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the disposal.
Key Dates
| Date | Description |
|---|---|
| 02/18/2025 | Date of transaction: David Rosa disposed of shares. |
| 02/20/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.